MARKET

MNLO

Menlo
MNLO
NASDAQ
Delisted
P/E
P/S
P/B
MARKET CAP
-2.0651
27.26
14.98
1,071,543,029.85
News
Financial
Releases
Corp Actions
Analysis
Profile
Were Hedge Funds Right About Piling Into Menlo Therapeutics Inc. (MNLO)?
The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. We at Insider Monkey have plowed through 821 13F filings that hedge funds and well-known value investors are
Insider Monkey · 08/07 13:03
Menlo Therapeutics EPS misses by $0.93, beats on revenue
Menlo Therapeutics (NASDAQ:MNLO): Q2 GAAP EPS of -$1.21 misses by $0.93. Revenue of $11.7M beats by $9.66M. Shares -1.9% PM. Press Release
seekingalpha · 08/06 16:13
Menlo Therapeutics Inc. (MNLO) Reports Q2 Loss, Tops Revenue Estimates
Menlo Therapeutics Inc. (MNLO) delivered earnings and revenue surprises of -476.19% and 472.94%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 08/06 15:25
Menlo Reports Second Quarter 2020 Financial Results and Provides Business Update
Conference Call Today at 8:30am Eastern TimeBRIDGEWATER, N.J., Aug. 06, 2020 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc. (Nasdaq: MNLO) (“Menlo” or the “Company”), a specialty pharmaceutical company focused on developing and commercializing proprietary therapi
GlobeNewswire · 08/06 11:00
Menlo Therapeutics to Report Second Quarter 2020 Financial Results on August 6
BRIDGEWATER, N.J., July 28, 2020 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc. (Nasdaq: MNLO) (“Menlo” or the “Company”), a specialty pharmaceutical company focused on developing and commercializing proprietary therapies to address unmet needs in dermatology, to
GlobeNewswire · 07/28 12:00
Hedge Funds Have Never Been This Bullish On Menlo Therapeutics Inc. (MNLO)
Insider Monkey · 06/23 18:21
Menlo Therapeutics Shares Up ~16% Following 13G Filing From Perceptive Advisors That Showed 14% Stake In Co.
Benzinga · 06/12 14:05
Menlo Therapeutics Inc.'s (NASDAQ:MNLO) Profit Outlook
Simply Wall St. · 06/11 12:34
More
No Data
Learn about the latest financial forecast of MNLO. Analyze the recent business situations of Menlo through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 7 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average MNLO stock price target is 8.61 with a high estimate of 24.00 and a low estimate of 3.000.
EPS
Institutional Holdings
Institutions: 157
Institutional Holdings: 86.18M
% Owned: 51.39%
Shares Outstanding: 167.69M
TypeInstitutionsShares
Increased
57
44.14M
New
59
6.98M
Decreased
11
1.57M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.13%
Pharmaceuticals & Medical Research
+0.30%
Key Executives
Chief Executive Officer/Director
David Domzalski
Chief Financial Officer/Treasurer
Andrew Saik
Chief Scientific Officer
Iain Stuart
Chief Compliance Officer
Ronald Krasnow
General Counsel
Mutya Harsch
Other
Matthew Wiley
Director
Sharon Barbari
Director
Rex Bright
Director
Anthony Bruno
Independent Director
Patrick LePore
Independent Director
Elisabeth Sandoval
  • Dividends
  • Splits
  • Insider Activity
No Data
  • All
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Menlo stock information, including NASDAQ:MNLO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MNLO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading MNLO stock methods without spending real money on the virtual paper trading platform.